- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05181839
A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
An Observational, Prospective, European, Multicentre, Mixed Methods Study to Describe the Lived Experience of X-Linked Hypophosphatemia (XLH) for Adolescents at End of Skeletal Growth
Study Overview
Detailed Description
This an observational, prospective, European, multicentre, mixed methods study that will involve the integration of quantitative and qualitative data exploring the lived experience of burosumab-treated adolescents with XLH at the end of skeletal growth. The study will involve two observation periods around the confirmed date of end of skeletal growth (index date)
The purpose of this study is to describe the lived experience of XLH for adolescents who are being treated with burosumab at the end of skeletal growth, with a focus on adolescent reported symptoms, activity duration and intensity, and wider burden, and to describe change over time for those who continue and discontinue burosumab at the end of skeletal growth. The study will also explore the experiences of carers at the time the adolescent reaches the end of skeletal growth.
The key objectives of this study are to:
- Describe the lived experience of adolescents with XLH who are being treated with burosumab within the 12 weeks prior to reaching the end of skeletal growth.
- Describe the lived experience of adolescents with XLH during the 26 weeks immediately after the end of skeletal growth, overall and according to whether they continue or discontinue burosumab treatment.
- Describe within-person changes in the lived experience of adolescents with XLH after reaching end of skeletal growth, in relation to their own pre-end of skeletal growth period.
- Explore the supportive care needs and burden on carers at the time the adolescent with XLH reaches end of skeletal growth.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Lille, France
- Recruiting
- Centre Hospitalier Universitair de Lille
-
Lyon, France
- Recruiting
- Hospices Civils de Lyon
-
Paris, France
- Recruiting
- APHP Paris - Assistance Publique Hopitaux de Paris
-
-
-
-
-
Groningen, Netherlands
- Recruiting
- University Medical Center Groningen - Beatrix Children's Hospital
-
-
-
-
-
Birmingham, United Kingdom
- Recruiting
- Birmingham Women's and Children's Hospital
-
Bristol, United Kingdom
- Recruiting
- Bristol Royal
-
Liverpool, United Kingdom
- Recruiting
- Alder Hay Children's Hospital
-
London, United Kingdom
- Recruiting
- Great Ormond Street Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Confirmed diagnosis of XLH (documented diagnosis of XLH in medical records, and evidence of at least one of the following: hypophosphataemia and/or impaired phosphate reabsorption due to elevated FGF23; PHEX mutation).
- Aged 12 to 17 years at start of study.
- Has open growth plates at enrolment and is estimated by their treating clinician to reach end of skeletal growth within the next 26 weeks (based on clinician's judgement in accordance with their normal approach used in routine practice).
- Has been receiving treatment with burosumab for at least study le (52 weeks).
- Provides informed consent to take part in the study (or provides assent, and carer provides consent, where applicable in accordance with specific country regulations).
Carer Inclusion Criteria:
- A main carer of a study participant (i.e. a parent or guardian who provides day-today support or care for the adolescent with XLH who is taking part in this study).
- Provides informed consent to take part in the study (for self and/or on behalf of eligible adolescent, where applicable in accordance with specific country regulations).
Exclusion Criteria:
- Unwilling and unable to participate in all aspects of the study (i.e. interviews, app, EQ- 5D-Y, wearable data collection) and /or does not agree to the collection of data from medical records.
- Missed two or more injections of burosumab in the past 6 months.
- Is planned to have any surgery during the study period.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Describe the lived experience of adolescents with XLH who are being treated with burosumab within the 12 weeks prior to reaching the end of skeletal growth.
Time Frame: 12 Weeks
|
Describe the lived experience of adolescents with XLH who are being treated with burosumab within the 12 weeks prior to reaching the end of skeletal growth.
|
12 Weeks
|
Describe the lived experience of adolescents with XLH during the 26 weeks immediately after the end of skeletal growth, overall and according to whether they continue or discontinue burosumab treatment.
Time Frame: 26 weeks
|
Describe the lived experience of adolescents with XLH during the 26 weeks immediately after the end of skeletal growth, overall and according to whether they continue or discontinue burosumab treatment.
|
26 weeks
|
Describe within-person changes in the lived experience of adolescents with XLH after reaching end of skeletal growth, in relation to their own pre-end of skeletal growth period.
Time Frame: Up to 52 weeks
|
Describe within-person changes in the lived experience of adolescents with XLH after reaching end of skeletal growth, in relation to their own pre-end of skeletal growth period.
|
Up to 52 weeks
|
Explore the supportive care needs and burden on carers at the time the adolescent with XLH reaches end of skeletal growth.
Time Frame: will be completed between weeks 21 and 25
|
Explore the supportive care needs and burden on carers at the time the adolescent with XLH reaches end of skeletal growth.
|
will be completed between weeks 21 and 25
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Kidney Diseases
- Urologic Diseases
- Nutrition Disorders
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Bone Diseases
- Metabolism, Inborn Errors
- Bone Diseases, Metabolic
- Renal Tubular Transport, Inborn Errors
- Calcium Metabolism Disorders
- Metal Metabolism, Inborn Errors
- Phosphorus Metabolism Disorders
- Rickets
- Vitamin D Deficiency
- Rickets, Hypophosphatemic
- Hypophosphatemia, Familial
- Familial Hypophosphatemic Rickets
- Hypophosphatemia
Other Study ID Numbers
- 2020-70-EU-CRY
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on X-Linked Hypophosphatemia
-
Kyowa Kirin Co., Ltd.Active, not recruiting
-
Kyowa Kirin Co., Ltd.Active, not recruitingX-linked Hypophosphatemia (XLH)China
-
Kyowa Kirin Pharmaceutical Development LtdActive, not recruitingX-Linked HypophosphatemiaSpain, Italy, United Kingdom, France, Belgium, Denmark, Germany, Hungary, Portugal, Norway, Switzerland, Israel, Netherlands, Czechia, Bulgaria, Sweden, Slovenia, Ireland, Latvia, Slovakia
-
Yale UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedHypophosphatemic Rickets, X Linked DominantUnited States
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletedX-Linked HypophosphatemiaKorea, Republic of, Canada, United States, Australia, Japan, United Kingdom, Sweden
-
Kyowa Kirin Co., Ltd.Active, not recruitingX-linked Hypophosphatemia (XLH)China
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletedX-Linked HypophosphatemiaUnited States
-
Wuerzburg University HospitalKyowa Kirin, Inc.Active, not recruiting
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingX-linked Hypophosphatemia (XLH)
-
Kyowa Kirin, Inc.CompletedX-Linked HypophosphatemiaUnited States
Clinical Trials on Burosumab
-
Wuerzburg University HospitalKyowa Kirin, Inc.Completed
-
Redwood Dermatology SciencesUltragenyx Pharmaceutical IncCompletedPain, Chronic | Hypophosphatemia | Hypophosphatemic RicketsUnited States
-
Ultragenyx Pharmaceutical IncKyowa Kirin Co., Ltd.AvailableX-linked Hypophosphatemia | Tumor-Induced Osteomalacia
-
Bicetre HospitalUnknownRare Diseases | X-linked HypophosphatemiaFrance
-
National Institute of Dental and Craniofacial Research...Active, not recruitingFibrous Dysplasia Of BoneUnited States
-
Laura TosiChildren's National Research Institute; Ultragenyx Pharmaceutical IncActive, not recruitingCutaneous Skeletal Hypophosphatemia Syndrome (CSHS) | Epidermal Nevus SyndromeUnited States
-
Kyowa Kirin, Inc.Kyowa Kirin Co., Ltd.CompletedX-Linked HypophosphatemiaUnited States
-
Kyowa Kirin Pharmaceutical Development LtdCompletedX-linked HypophosphatemiaUnited Kingdom, France, Ireland, Italy
-
Kyowa Kirin Pharmaceutical Development LtdCompletedX-linked Hypophosphatemia (XLH)Sweden, Spain, United Kingdom, Italy, Austria, France
-
Kyowa Kirin Co., Ltd.Active, not recruitingTumor-Induced Osteomalacia (TIO)China